Servier

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Approved for marketing

Vorasidenib Expanded Access Program

Earlier

Oct 18, 2024TrialPhase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Aug 6, 2024FDAVoranigo — VORANIGO

Oct 10, 2023TrialA Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Dec 20, 2018FDAASPARLAS — ASPARLAS

Jul 20, 2018FDATibsovo — TIBSOVO

Jun 25, 2018TrialTrifluridin/tipirACil in MeTastatIc Colorectal Cancer

May 14, 2018TrialEvaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

8 patent groups across drugs · Source: FDA Orange Book

DrugExpires

TibsovoJun 21, 2030 Tibsovo4 patentsJan 18, 2033 Voranigo3 patentsJul 11, 2034 Tibsovo3 patentsMar 13, 2035 VoranigoDec 4, 2035 TibsovoOct 18, 2036 VoranigoJan 16, 2039 TibsovoJun 7, 2039

Regulatory

Regulatory Timeline

19941 event

FDAFeb 1

Oncaspar — ONCASPAR

Application BLA103411 (BLA)

20182 events

FDADec 20

ASPARLAS — ASPARLAS

Application BLA761102 (BLA)

FDAJul 20

Tibsovo — TIBSOVO

Application NDA211192 (NDA)

20241 event

FDAAug 6

Voranigo — VORANIGO

Application NDA218784 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)